This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

The Real Winners of Drug Experimentation

Drug industry executives often point out that it costs more than $800 million to bring a compound from the laboratory to the marketplace. And of every 5,000 to 10,000 screened compounds, the industry's top trade group says, only five will make it to clinical testing, and only one will be approved by regulators.

Those are daunting figures for drug and biotech companies, whose stocks can bounce around depending on whether an experimental compound is a blockbuster or a bust. However, for companies that provide R&D goods and services to drugmakers, nothing succeeds like trial and error.

These companies, such as Sigma-Aldrich (SIAL) and Invitrogen (IVGN), can do quite well whether a drugmaker such as Pfizer (PFE) produces a hit like Lipitor or a failure like torcetrapib, a cholesterol drug that never made it to market.

These companies make chemicals, reagents, bioassays, cell cultures, test tubes, diagnostic kits and other so-called life-sciences tools. As long as R&D budgets grow, so should sales for companies like Applied Biosystems (ABI) and Qiagen (QGEN).

Among drug industry executives and analysts, pharmaceutical companies like Merck (MRK) and Genentech (DNA) often have been likened to miners during the California Gold Rush. In following that mining analogy, life-science tool firms are akin to the Gold Rush merchants who sold picks, shovels and assay equipment.

The mining analogy has become a cliche, but truth is a foundation for cliches. Many Gold Rush merchants fared better than the miners they supplied, and many of today's pick-and-shovel firms have fared better than their clients.

Sigma-Aldrich's stock gained 40% for the 12 months ended March 20, while the Amex pharmaceutical index, which represents large drug companies, was off 13%. The Amex biotechnology index was down 5%, and the S&P 500 fell 6% over the same period.

Over the past five years, St. Louis-based Sigma-Aldrich's shares gained 167% on a split-adjusted basis, while the S&P 500 rose 52%, the biotechnology index climbed 102%, and the big-drug stock index barely broke even during the same time frame.

Other picks-and-shovels players have done well, too. Over the past 12 months, shares of Qiagen, Applied Biosystems, Invitrogen and Thermo Fisher Scientific (TMO) each outpaced the biotech, drug and broader stock indices. Over five years, shares of these companies are up between 109% and 220%.

However, these stocks aren't slam-dunks for consistent returns. On a split-adjusted basis, Qiagen climbed to $57 by mid-2000, then lost more than 90% of its value in just over two years. It has rebounded to trade in the high teens or low $20s. Shares of Millipore (MIL), were down 7% for the 12 months ended March 20, although the stock has doubled over five years.

Aside from company-specific problems, analysts say the major hurdles to picks-and-shovels firms maintaining solid growth rates are extensive drug-industry consolidation, cutbacks in pharmaceutical R&D and slowdowns in government research activities.

Wall Street's worries will be reduced for companies that can expand their products and services in foreign markets, especially developing countries. Survival of the fittest also may mean survival of the biggest in an industry for which consolidation continues.

1 of 3

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 16,493.37 -69.93 -0.42%
S&P 500 1,925.15 -5.52 -0.29%
NASDAQ 4,352.6390 -17.1340 -0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs